TEXT

Top Abstract Text References

Cationic lipid-mediated gene transfer (lipofection) is one of the standard transfection methods for introducing foreign genes into mammalian cells (7). The simplicity of this technique, its lack of toxicity, and its largely nonimmunogenic properties, as well as the ability of liposomes to deliver large pieces of DNA, make lipofection an attractive alternative under some conditions to viral gene delivery not only in vitro but also in vivo (8, 10). For instance, Zhu et al. have shown that liposome-mediated gene delivery to a large number of organs is feasible after intravenous injection, although under these conditions DNA delivery and transgene expression were most efficient for the macrophage populations in lung or spleen tissue (29). Nabel and colleagues have also demonstrated that direct intratumoral injection of DNA-lipid complex containing the HLA-B7 gene can provoke an immune response that can in turn lead to some degree of tumor stabilization or even regression around the injected region, as well as at distant metastases, with no evidence of detectable toxicity associated with the treatment (19).

Although liposome-mediated gene transfer has advanced to the point of justifying clinical trials, gene transfer by liposomes is still much less efficient than viral vector-mediated transfer. Zabner et al. have suggested that the inefficiency of lipid-mediated DNA transfer may be due to events subsequent to endocytosis of the DNA-lipid complexes into cells, especially to inefficient release into the cytoplasm of intact DNA from endocytosed vesicles and inefficient nuclear localization (26).

It is well known that the envelope spike G glycoprotein of vesicular stomatitis virus (VSV-G) can be incorporated into the envelopes of other viruses to produce pseudotyped particles with new host ranges and cell tropisms (27). Our laboratory has reported general and efficient methods for pseudotyping murine leukemia virus (MLV)-derived retrovirus vectors with VSV-G (4-6, 25). More recently, the tools and techniques of VSV-G pseudotyping have been used for the production of lentivirus-based vectors (21). Because of the pantropic characteristics of the VSV-G envelope, VSV-G-pseudotyped vectors allow efficient gene transfer into many cell types refractory to other methods of gene transfer. It has been reported that purified VSV-G can spontaneously reconstitute into the lipid bilayer; however, the conditions required for the conservation of its fusogenic activity in such lipids have not been fully defined, and the role of VSV-G in producing efficient gene transfer liposomes has not been reported (14, 17, 22).

We have recently demonstrated that VSV-G particles are efficiently released into culture medium from cells expressing VSV-G and that VSV-G prepared from such conditioned medium can be introduced into the membranes of spikeless, immature, noninfectious MLV-based retrovirus-like particles in a cell-free system to generate infectious virus particles in vitro (2, 23). In the present study, we report that VSV-G prepared from conditioned medium of VSV-G-expressing cells can also be introduced into lipofection complexes to produce fusogenic VSV-G liposomes that demonstrate a markedly enhanced lipofection efficiency and that abrogate the serum inhibition of gene transfer by conventional lipofection complexes.

VSV-G purification. VSV-G protein was prepared from conditioned medium of 293 cells transfected with plasmid pCMV-G expressing VSV-G by the calcium phosphate coprecipitation method as previously described (25). The conditioned medium was centrifuged at 24,000 rpm with a Beckman SW28 rotor for 90 min, and the pelleted VSV-G was resuspended with phosphate-buffered saline (PBS) (pH 7.5). To partially purify the VSV-G, the suspension of the pellet was layered onto 5 to 30% continuous sucrose gradients in PBS for velocity sedimentation. The gradients were centrifuged at 30,000 rpm in an SW41Ti rotor for 25 min, and fractions containing VSV-G were collected, diluted with PBS, and centrifuged at 30,000 rpm for 90 min. The resulting VSV-G pellet was resuspended with PBS, and the amount of protein was quantified with the bicinchoninic acid protein detection kit (Pierce, Rockford, Ill.). The proteins were analyzed by sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis on a 7.5% gel and were visualized with the silver staining kit (Bio-Rad, Richmond, Calif.). Identification of the VSV-G band was confirmed by Western blot analysis with anti-VSV-G monoclonal antibody P5D4 (Sigma, St. Louis, Mo.) (1). The VSV-G in pellets of transfected cells was detected as a band of approximately 68 kDa in size, with significant amounts 75 kDa, probably representing bovine serum albumin (Fig. 1, lane 1). After velocity sucrose gradient sedimentation and repelleting, the purity of the VSV-G was substantially improved, as judged by silver staining (Fig. 1, lane 2). Approximately 20 to 30 µg of VSV-G protein from 200 ml of conditioned medium from 293 cells transfected with pCMV-G was routinely obtained.

View larger version (66K): [in this window] [in a new window]   FIG. 1.   SDS-polyacrylamide gel electrophoresis of partially purified VSV-G. The conditioned medium of 293 cells transfected with pCMV-G was centrifuged, and the resulting pellet was examined by electrophoresis (lane 1). The pellet suspension was subjected to velocity sucrose gradient, and VSV-G-containing fractions were pooled, diluted with PBS, and repelleted. The repurified pellet suspension was analyzed as described above (lanes 2 and 3). About 100 ng of protein in each VSV-G preparation was loaded and visualized by silver staining (lanes 1 and 2) and by Western blot analysis with anti-VSV-G monoclonal antibody, P5D4 (lane 3).

VSV-G-induced enhancement of Lipofectin-mediated DNA transfer. The effect of VSV-G on lipofection was examined by using Lipofectin (GIBCO BRL/Life Technologies, Grand Island, N.Y.). The DNA-lipid complexes were prepared according to the manufacturer's instructions and were mixed with VSV-G just before transfection. All transfections were performed on cell cultures at approximately 80% confluency. BHK and 293 cells grown in six-well plates were washed twice with Dulbecco modified Eagle medium (DMEM), were maintained in fresh DMEM containing 10% fetal bovine serum (FBS), and were incubated with the DNA-lipid complex. The DNA-lipid complex was prepared with reduced volume as follows. A 5-µg amount of Lipofectin was diluted with 100 µl of DMEM for each well. After incubation for 30 min at room temperature, the diluted Lipofectin was mixed with 100 µl of DMEM containing 1 µg of plasmid pCMV-luc expressing the firefly luciferase gene, and the mixture was incubated for 15 min at room temperature and subjected to transfection. Culture medium was changed with fresh DMEM with 10% FBS after 12 h of incubation. Luciferase activity in the transfected cells was measured 2 days after lipofection and was presented as relative light units (RLU) per microgram of cellular protein, as previously described (15). To examine the stable transformant, 293 cells were transfected with plasmid pcDNA3 (Invitrogen, Carlsbad, Calif.), which contains the neomycin resistance gene driven by the simian virus 40 promoter, serially diluted cells were spread on 10-cm plates 24 h after transfection, and G418 selection was started 48 h after transfection. G418-resistant colonies were counted after 2 weeks of selection (15). As shown in Table 1, addition of VSV-G into the DNA-lipid complex increased the lipofection efficiency by approximately 10-fold in the presence of 10% FBS in the culture medium, as estimated by luciferase activities in both BHK and 293 cells or by the numbers of stable, G418-resistant colonies of 293 cells. In all cases, this enhanced transfection was inhibited by anti-VSV-G neutralizing antibody I1 (4). We also examined the enhancing effect with a fusion-defective VSV-G mutant, VSV-G-P127L. The mutant VSV-G-P127L contains a mutation encoding a proline-to-leucine substitution at amino acid 127 and was made by use of the MORPH in vitro mutagenesis kit (5prime3prime, Inc., Boulder, Colo.). The mutagenesis primer 5'-ATATCCACAACTCTGCAGAGGGAACCCGGGATTCAGCCA-3' also includes a number of silent mutations (underlined bases). An identical mutant was previously reported by Zhang and Ghosh (28). Although VSV-G-P127L is expressed well on the cell surface and is released efficiently into culture medium (2), its cell fusion function is less than 5% of that of wild-type VSV-G (9, 16, 28). The VSV-G-P127L that was prepared and used by the method used for wild-type VSV-G in the lipofection experiment did not show any enhancing effect on lipofection (Table 1). Therefore, we conclude that the enhancement of lipofection by VSV-G requires the fusogenic function of VSV-G. Neither luciferase activity nor G418 resistance was seen after exposure of the cells to DNA or VSV-G without Lipofectin (data not shown).

Optimization of VSV-G-dependent increase in Lipofection efficiency. To optimize the composition of the Lipofectin-DNA-VSV-G complexes during lipofection, we examined the effect of increasing amounts of VSV-G added to constant amounts (2.5 µg) of the lipid-DNA complex immediately prior to addition to the cells. As shown in Fig. 2, when 2.5 µg of lipid-DNA was mixed just before transfection with amounts of partially purified VSV-G ranging from 10 ng to 1 µg, the efficiency of lipofection on both BHK and 208F cells increased in a dose-dependent manner and reached a maximum efficiency at approximately 300 to 400 ng of VSV-G. Amounts of VSV-G that were greater than 400 ng slightly decreased the transfection efficiency, although the decrease was not correlated with the known toxic effect of VSV-G, i.e., the formation of syncytium.

View larger version (11K): [in this window] [in a new window]   FIG. 2.   The effect of increasing amounts of the partially purified VSV-G on lipofection efficiency in BHK and 208F cells (6). Increasing amounts of partially purified VSV-G in the form of pelleted conditioned medium from transfected 293 cells were added to the DNA-lipid complex (2.5 µg of Lipofectin and 0.5 µg of pCMV-luc per well) immediately prior to addition to cells. Transfection was performed with 12-well plates in DMEM with 10% FBS. The experiment was performed in triplicate, and the data are means ± standard deviations.

Effect of serum in culture medium on transfection efficiency. In many cell lines, the maximum efficiency of lipofection is known to require serum-depleted or serum-free medium, even though such conditions are themselves toxic to many cell types. For such cell lines, it would be advantageous to have lipofection conditions that allow efficient gene transfer in the presence of serum. Therefore, we examined the effect of serum on lipofection in the presence of VSV-G. Cells grown in 12-well plates were washed twice with DMEM and were maintained in fresh DMEM containing various concentrations of FBS, and the plates were incubated with the DNA-lipid complex or the DNA-lipid-VSV-G complex. As shown in Fig. 3, lipofection efficiency was, as expected, dramatically inhibited by serum in the absence of VSV-G. However, in the presence of VSV-G, serum-mediated inhibition of lipofection was completely abrogated. In the case of BHK cells, high concentrations of serum may even have a further enhancing effect on lipofection efficiency.

View larger version (15K): [in this window] [in a new window]   FIG. 3.   Effect of the concentration of serum in culture medium on VSV-G-induced lipofection efficiency. Aliquots of partially purified VSV-G (200 ng) were added to the DNA-lipid complex immediately before addition to cells in 12-well plates in DMEM supplemented with various concentrations of FBS. The experiment was performed in triplicate, and the data are means ± standard deviations.

Physical association between VSV-G and DNA-lipid complexes. To examine the mechanism of the VSV-G-mediated enhancement of lipofection, we analyzed the association of VSV-G with the lipid-DNA complex by equilibrium buoyant density sucrose gradient sedimentation. Partially purified VSV-G (2.5 µg), DNA-lipid complex (50 µg of lipid and 10 µg of pCMV-luc), or VSV-G-DNA-lipid conjugate (2.5 µg of VSV-G, 50 µg of lipofectin, and 10 µg of pCMV-luc) was layered onto 5 to 40% continuous sucrose gradients prepared in PBS (pH 7.5). The gradients were centrifuged at 35,000 rpm in an SW41Ti rotor for 16 h at 4°C. Fractions were collected from the top of the gradient. Transfection efficiency was measured by determining luciferase activity under the serum-free conditions described above. VSV-G was detected by established Western blotting methods (1) by using anti-VSV-G monoclonal antibody P5D4. As shown in Fig. 4, the buoyant density of uncomplexed VSV-G is approximately 1.10 to 1.15 g/ml. The formation of the lipid-DNA-VSV-G complex results in a shift of the buoyant density of some of the VSV-G to approximately 1.05 g/ml, a position that corresponds to the lipofection maximum of the sample. Interestingly, the position of maximal infectivity of the VSV-G liposome was several fractions heavier than that of the Lipofectin-DNA complex itself, which is a result consistent with the presence of added VSV-G protein in the VSV-G liposome.

View larger version (21K): [in this window] [in a new window]   FIG. 4.   Buoyant-density analysis by sucrose density gradient centrifugation of uncomplexed VSV-G, Lipofectin-DNA complex, and Lipofectin-DNA-VSV-G complexes. (A) Luciferase activities (represented by the total activity of each fraction) in BHK cells transfected with gradient fractions containing the Lipofectin-DNA complex or the Lipofectin-DNA-VSV-G complex; (B) Western blot analysis of fractions from the gradient containing pelleted VSV-conditioned medium from transfected, VSV-G-producing 293 cells and from a gradient containing the Lipofectin-DNA-VSV-G liposome. VSV-G protein was detected with the anti-VSV-G monoclonal antibody P5D4. Sucrose densities are indicated as the densities in parallel gradients.